Targeting FtsZ for antituberculosis drug discovery: noncytotoxic taxanes as novel antituberculosis agents. - Wikidata - wikimedia - TriplyDB

Targeting FtsZ for antituberculosis drug discovery: noncytotoxic taxanes as novel antituberculosis agents.

Targeting FtsZ for antituberculosis drug discovery: noncytotoxic taxanes as novel antituberculosis agents.

http://www.wikidata.org/entity/Q36857437

about

Mycobacterium tuberculosis septum site determining protein, Ssd encoded by rv3660c, promotes filamentation and elicits an alternative metabolic and dormancy stress response Targeting the Wolbachia cell division protein FtsZ as a new approach for antifilarial therapy Artificial polyploidy improves bacterial single cell genome recovery Assembly dynamics of Mycobacterium tuberculosis FtsZ Morphological features and signature gene response elicited by inactivation of FtsI in Mycobacterium tuberculosis A trisubstituted benzimidazole cell division inhibitor with efficacy against Mycobacterium tuberculosis Rational design of berberine-based FtsZ inhibitors with broad-spectrum antibacterial activity FtsZ in bacterial cytokinesis: cytoskeleton and force generator all in one.Comparison of small molecule inhibitors of the bacterial cell division protein FtsZ and identification of a reliable cross-species inhibitor.SB-RA-2001 inhibits bacterial proliferation by targeting FtsZ assembly.Synthesis and preliminary biological evaluation of high-drug-load paclitaxel-antibody conjugates for tumor-targeted chemotherapy Novel trisubstituted benzimidazoles, targeting Mtb FtsZ, as a new class of antitubercular agents.Challenges of antibacterial discovery In vitro-in vivo activity relationship of substituted benzimidazole cell division inhibitors with activity against Mycobacterium tuberculosis.Drug discovery targeting cell division proteins, microtubules and FtsZ.Antibiotics and bacterial resistance in the 21st century.Discovery of anti-TB agents that target the cell-division protein FtsZ.Benzimidazole-based antibacterial agents against Francisella tularensis.MazF6 toxin of Mycobacterium tuberculosis demonstrates antitoxin specificity and is coupled to regulation of cell growth by a Soj-like protein.Novel pyridopyrazine and pyrimidothiazine derivatives as FtsZ inhibitors.Cell division inhibitors with efficacy equivalent to isoniazid in the acute murine Mycobacterium tuberculosis infection model.Diterpenes as lead molecules against neglected tropical diseases.Strategic incorporation of fluorine in the drug discovery of new-generation antitubercular agents targeting bacterial cell division protein FtsZ.Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors.New drugs and regimens for treatment of TB.An FtsZ-targeting prodrug with oral antistaphylococcal efficacy in vivo Targeting FtsZ for antibacterial therapy: a promising avenue.SAR studies on trisubstituted benzimidazoles as inhibitors of Mtb FtsZ for the development of novel antitubercular agents.A bactericidal guanidinomethyl biaryl that alters the dynamics of bacterial FtsZ polymerization.Recent advances in antituberculous drug development and novel drug targets.Therapeutic potential of FtsZ inhibition: a patent perspective.The development of FtsZ inhibitors as potential antibacterial agents.Recent advances in the discovery and development of antibacterial agents targeting the cell-division protein FtsZ.Identification of agents targeting FtsZ assembly.MadR1, a Mycobacterium tuberculosis cell cycle stress response protein that is a member of a widely conserved protein class of prokaryotic, eukaryotic and archeal origin Enterococcal and streptococcal resistance to PC190723 and related compounds: molecular insights from a FtsZ mutational analysis.Mutation at G103 of MtbFtsZ Altered their Sensitivity to Coumarins Promoting assembly and bundling of FtsZ as a strategy to inhibit bacterial cell division: a new approach for developing novel antibacterial drugs.The interactions of cell division protein FtsZ with guanine nucleotides.Plumbagin inhibits cytokinesis in Bacillus subtilis by inhibiting FtsZ assembly--a mechanistic study of its antibacterial activity.

P2860

Q21263107-E83869F1-5557-4A8B-84E7-5DDF3562CBB6 Q28478176-E86D0974-8459-49DE-8212-FA9355F6F096 Q28483890-C87C9138-E497-4EAE-885B-AEDD102B2BA4 Q28486940-0F475538-FD3A-4D04-8B5A-C6F6F7879D15 Q28487277-51B525EB-6B31-4A55-8CB3-C2DD929305AC Q28537897-6C1368A4-F99D-43CC-83B8-2083E27002CF Q28538766-7613DFE9-D4A1-4957-959E-F5707992A077 Q30497729-8DB5F92A-6D20-4CEB-8D3F-2266A9EA4CC2 Q31089800-A0DA0422-449F-4FFA-BD98-D8997725174F Q33609157-7E30EDE3-D436-4773-BAE9-D6CD1F17ABE5 Q33737986-CF23E712-92DE-4927-AE60-B4D10CEB6D50 Q33761632-023D9581-467D-4421-B0A2-37B6BFD8366C Q33793074-6D46452F-1C77-4B61-9485-9F6D0E023112 Q33797084-2139FB96-563C-4EE8-91E7-5AA474AC321C Q34143487-0603D014-4FB5-4999-887F-B7F28762DCD5 Q34156349-64FAD652-8F6D-448D-BC9D-2FA678E7D2C1 Q34576179-F04748E1-F0AF-40BC-9AA0-58FA4E671BEC Q34691423-51FFB567-3DD0-400B-A5DA-2FB69C1E065E Q35028889-3F0E2AB6-C973-4087-B10F-5F04B74B1B3C Q35550698-773AE177-E457-404E-B270-7B1F29AEEE28 Q36185304-0BAE524C-7DF8-4C43-A567-88ABA3E1872C Q36206465-5A555817-0B26-4C2B-95BF-90F08FDD91B8 Q36384231-52786171-FA7D-47AD-B369-1AA232A76FD4 Q36800124-0BBF30AA-8E20-4DC6-A34C-2ED74C66FD8A Q36825354-236C1421-7460-401A-9AC9-3E76DB116682 Q37335812-A2D18AE0-DB72-4A41-BD96-5A723B78464D Q37573808-D9519E93-7938-4D98-B510-88C68F7CF402 Q37600601-4DEEEAB8-418B-4BD8-B843-E6BECB1E11B9 Q37671492-DF3C0AB7-2FC3-4548-9142-937D5F7A5FF2 Q37754884-CF53320E-1099-4406-9AC2-FBB8B87AD97D Q37854070-D0F63F11-05AB-4CB7-B7A2-02F57E84407A Q38013726-8EB985CE-E452-4F8C-ABD5-FC0DE0CFE5F5 Q38836958-CFC9AD4A-C25A-4480-A448-166D710A8F37 Q38855290-E2F5C286-2145-4858-B46A-B0644076E251 Q40587576-DABC4828-2830-4731-B016-3A525D702B45 Q41003090-EB3F81AB-0326-4A86-A7B9-428A5F424644 Q42292706-2045D45C-84EE-4DF9-8C25-5ECA200933B7 Q45937068-95571D30-EDE2-4064-8C33-A132FE741077 Q46918546-FD74B54E-3966-46AD-81A8-C99B6982ED17 Q48032989-91A38D8D-1CC0-4661-8809-C21D5FE888F5

P2860

Targeting FtsZ for antituberculosis drug discovery: noncytotoxic taxanes as novel antituberculosis agents.

http://www.wikidata.org/entity/Q36857437

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

Targeting FtsZ for antitubercu ...... novel antituberculosis agents.

@en

type

label

Targeting FtsZ for antitubercu ...... novel antituberculosis agents.

@en

prefLabel

Targeting FtsZ for antitubercu ...... novel antituberculosis agents.

@en

P1433

Q36857437-BABDA8A0-FF36-4D59-9AA5-C3E04AC9763D

P1476

Q36857437-9AA75580-BA43-44AD-8679-D972F68F7562

P2093

Q36857437-57F29DD0-2F95-485C-9847-E62855A0CD7D

Q36857437-70D9D638-72FA-43E3-9235-27978892C7A5

Q36857437-73C4FDBC-11BA-4DCA-907D-F4F9C22AF6AB

Q36857437-974519E2-D3BB-47C7-BBAB-554562EB1409

Q36857437-9BB33F0B-53C8-4FDD-878A-A107841898A9

Q36857437-AA2E086F-8E3D-48E7-B13F-3A53A0566850

P2860

Q36857437-0F2FFEE9-8C9E-4AC6-A34A-93CE324FDF77

Q36857437-28D49DAE-C80A-4F69-A8B9-8B47900C39D2

Q36857437-45DEB383-7BC5-4B60-A30D-1456622EEF66

Q36857437-5DF24214-D779-4AEA-BF6C-DE73E79558AE

Q36857437-790AE030-9F62-4193-A87E-2C78D9D48147

Q36857437-8489AA3F-53BD-4773-B4DC-D31B5D9E50E6

Q36857437-951F4BD3-66C6-4E92-B4B6-F333E1F5AE9F

Q36857437-E8F4A7E5-8CD8-45E6-8F48-CE5278072434

P304

Q36857437-E269B10C-AD63-40D1-A7F0-8AB8CCCF8F05

P31

Q36857437-067FE4D2-C692-429A-9BC6-A13ADC8B6BF3

P356

Q36857437-C0B86A72-9B86-41FC-A322-B006E195DAA9

P407

Q36857437-B8C5E2E3-B71A-417E-8990-F3919D55036F

P433

Q36857437-08E13CC4-7F72-46F7-A7F7-5F620FB05B34

P478

Q36857437-7CFBC226-E979-4C71-9A5F-6B5B25894171

P50

Q36857437-3AAAC991-76BE-4253-B3D7-C2687668B3D7

Q36857437-47E02586-BC68-480D-987F-0C7C37126518

Q36857437-661D0470-3BC0-4A75-95F8-0F4ECF736D7A

P577

Q36857437-C00A4321-7CE7-40CE-B55D-8A740BBE6358

P5875

Q36857437-88EAD26C-B136-4705-9772-15D4FC0BF46E

P698

Q36857437-3AFEEBDA-07E9-40D3-9273-87C8A6AF47E6

P932

Q36857437-0655D1A4-C33D-4BEE-A4B2-EAA0B66DBA6B

P356

P1433

Journal of Medicinal Chemistry

P1476

Targeting FtsZ for antitubercu ...... novel antituberculosis agents.

@en

P2093

Amol Amin

http://www.w3.org/2001/XMLSchema#string

Antonella Pepe

http://www.w3.org/2001/XMLSchema#string

Fumiko Kirikae

http://www.w3.org/2001/XMLSchema#string

Laurel Respicio

http://www.w3.org/2001/XMLSchema#string

Qing Huang

http://www.w3.org/2001/XMLSchema#string

Teruo Kirikae

http://www.w3.org/2001/XMLSchema#string

P2860

FtsZ ring structure associated with division in Escherichia coli

Taxane-based reversal agents modulate drug resistance mediated by P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein.

Issues facing TB control (7). Multiple drug-resistant tuberculosis.

The chemistry of taxol and related taxoids.

Design, synthesis and structure-activity relationships of novel taxane-based multidrug resistance reversal agents.

Structure-activity analysis of taxane-based broad-spectrum multidrug resistance modulators.

Broad-spectrum modulation of ATP-binding cassette transport proteins by the taxane derivatives ortataxel (IDN-5109, BAY 59-8862) and tRA96023.

Antiangiogenic and antitumor activity of IDN 5390, a new taxane derivative.

P304

463-466

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1021/JM050920Y

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

49

http://www.w3.org/2001/XMLSchema#string

P50

Richard Slayden

P577

2006-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7352626

http://www.w3.org/2001/XMLSchema#string

P698

16420032

http://www.w3.org/2001/XMLSchema#string

P932

2527599

http://www.w3.org/2001/XMLSchema#string